 Pharmacokinetics patients AIDS AIDS-related complex tetrahydroimidazobenzodiazepinthione TIBO potent activity human immunodeficiency virus vitro patients AIDS AIDS-related complex dose-escalating pilot study Doses mg intravenous infusion weeks haematological biochemical evidence toxicity Mean cell count second month treatment steady-state plasma concentrations drug Median antigen concentration first month therapy rise antigen therapy fall treatment end-point analysis significant difference combination potent antiretroviral activity vitro observed effect HIV antigen absence toxicity vivo indicate related TIBO derivatives study treatment retroviral infections